Nivolumab as maintenance therapy following platinum‐based chemotherapy in 
EGFR‐mutant lung cancer patients after tyrosine kinase inhibitor failure: A single‐arm, open‐label, phase 2 trial. This evidence concerns the gene EGFR and lung carcinoma.